nodes	percent_of_prediction	percent_of_DWPC	metapath
Enzalutamide—ABCB1—colon cancer	0.388	1	CbGaD
Enzalutamide—CYP2B6—Irinotecan—colon cancer	0.0539	0.113	CbGbCtD
Enzalutamide—ALB—Irinotecan—colon cancer	0.0529	0.111	CbGbCtD
Enzalutamide—ALB—Fluorouracil—colon cancer	0.0507	0.107	CbGbCtD
Enzalutamide—CYP2C9—Capecitabine—colon cancer	0.0461	0.097	CbGbCtD
Enzalutamide—CYP3A5—Irinotecan—colon cancer	0.0425	0.0894	CbGbCtD
Enzalutamide—CYP2C8—Fluorouracil—colon cancer	0.0392	0.0825	CbGbCtD
Enzalutamide—CYP3A5—Vincristine—colon cancer	0.0371	0.0781	CbGbCtD
Enzalutamide—ALB—Methotrexate—colon cancer	0.028	0.0589	CbGbCtD
Enzalutamide—ABCB1—Irinotecan—colon cancer	0.0277	0.0582	CbGbCtD
Enzalutamide—CYP2C9—Fluorouracil—colon cancer	0.0273	0.0575	CbGbCtD
Enzalutamide—ABCB1—Vincristine—colon cancer	0.0242	0.0509	CbGbCtD
Enzalutamide—CYP3A4—Irinotecan—colon cancer	0.0166	0.0349	CbGbCtD
Enzalutamide—ABCB1—Methotrexate—colon cancer	0.0146	0.0308	CbGbCtD
Enzalutamide—CYP3A4—Vincristine—colon cancer	0.0145	0.0305	CbGbCtD
Enzalutamide—AR—scrotum—colon cancer	0.0119	0.337	CbGeAlD
Enzalutamide—Lung infection—Methotrexate—colon cancer	0.00379	0.046	CcSEcCtD
Enzalutamide—Lower respiratory tract infection—Capecitabine—colon cancer	0.00245	0.0297	CcSEcCtD
Enzalutamide—ALB—gall bladder—colon cancer	0.0021	0.0594	CbGeAlD
Enzalutamide—Cognitive disorder—Methotrexate—colon cancer	0.00144	0.0175	CcSEcCtD
Enzalutamide—Haematoma—Capecitabine—colon cancer	0.00133	0.0161	CcSEcCtD
Enzalutamide—Musculoskeletal pain—Vincristine—colon cancer	0.0013	0.0157	CcSEcCtD
Enzalutamide—Laryngitis—Capecitabine—colon cancer	0.00116	0.0141	CcSEcCtD
Enzalutamide—Sepsis—Irinotecan—colon cancer	0.00108	0.0131	CcSEcCtD
Enzalutamide—Multiple fractures—Methotrexate—colon cancer	0.00107	0.013	CcSEcCtD
Enzalutamide—Fracture—Methotrexate—colon cancer	0.00107	0.013	CcSEcCtD
Enzalutamide—Memory impairment—Capecitabine—colon cancer	0.00107	0.0129	CcSEcCtD
Enzalutamide—Sepsis—Fluorouracil—colon cancer	0.00104	0.0126	CcSEcCtD
Enzalutamide—Injury—Irinotecan—colon cancer	0.000987	0.012	CcSEcCtD
Enzalutamide—AR—epithelium—colon cancer	0.000943	0.0267	CbGeAlD
Enzalutamide—Musculoskeletal stiffness—Capecitabine—colon cancer	0.000932	0.0113	CcSEcCtD
Enzalutamide—Amnesia—Fluorouracil—colon cancer	0.000925	0.0112	CcSEcCtD
Enzalutamide—AR—smooth muscle tissue—colon cancer	0.000908	0.0257	CbGeAlD
Enzalutamide—AR—renal system—colon cancer	0.000875	0.0248	CbGeAlD
Enzalutamide—Muscular weakness—Vincristine—colon cancer	0.000822	0.00996	CcSEcCtD
Enzalutamide—Dry skin—Fluorouracil—colon cancer	0.000796	0.00965	CcSEcCtD
Enzalutamide—Nasopharyngitis—Fluorouracil—colon cancer	0.000777	0.00942	CcSEcCtD
Enzalutamide—Muscular weakness—Fluorouracil—colon cancer	0.000766	0.00929	CcSEcCtD
Enzalutamide—Neutropenia—Vincristine—colon cancer	0.000753	0.00913	CcSEcCtD
Enzalutamide—ABCB1—blood vessel—colon cancer	0.000751	0.0213	CbGeAlD
Enzalutamide—Neutropenia—Irinotecan—colon cancer	0.000733	0.00889	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Irinotecan—colon cancer	0.000729	0.00883	CcSEcCtD
Enzalutamide—AR—lymphoid tissue—colon cancer	0.000726	0.0206	CbGeAlD
Enzalutamide—Sepsis—Capecitabine—colon cancer	0.000726	0.0088	CcSEcCtD
Enzalutamide—Pneumonia—Vincristine—colon cancer	0.000722	0.00875	CcSEcCtD
Enzalutamide—AR—digestive system—colon cancer	0.000717	0.0203	CbGeAlD
Enzalutamide—CYP2C8—renal system—colon cancer	0.000707	0.02	CbGeAlD
Enzalutamide—Pneumonia—Irinotecan—colon cancer	0.000703	0.00852	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Fluorouracil—colon cancer	0.000698	0.00846	CcSEcCtD
Enzalutamide—Musculoskeletal stiffness—Methotrexate—colon cancer	0.000694	0.00841	CcSEcCtD
Enzalutamide—Pneumonia—Fluorouracil—colon cancer	0.000673	0.00816	CcSEcCtD
Enzalutamide—Infestation NOS—Fluorouracil—colon cancer	0.00067	0.00812	CcSEcCtD
Enzalutamide—Infestation—Fluorouracil—colon cancer	0.00067	0.00812	CcSEcCtD
Enzalutamide—CYP2C19—digestive system—colon cancer	0.000665	0.0188	CbGeAlD
Enzalutamide—Hot flush—Capecitabine—colon cancer	0.000649	0.00787	CcSEcCtD
Enzalutamide—Amnesia—Capecitabine—colon cancer	0.000646	0.00783	CcSEcCtD
Enzalutamide—Menopausal symptoms—Capecitabine—colon cancer	0.000643	0.0078	CcSEcCtD
Enzalutamide—Hypoaesthesia—Vincristine—colon cancer	0.000641	0.00777	CcSEcCtD
Enzalutamide—CYP3A5—renal system—colon cancer	0.000638	0.0181	CbGeAlD
Enzalutamide—Urinary tract disorder—Vincristine—colon cancer	0.000636	0.00771	CcSEcCtD
Enzalutamide—CYP2B6—renal system—colon cancer	0.000634	0.018	CbGeAlD
Enzalutamide—AR—vagina—colon cancer	0.000633	0.0179	CbGeAlD
Enzalutamide—Connective tissue disorder—Vincristine—colon cancer	0.000633	0.00768	CcSEcCtD
Enzalutamide—Urethral disorder—Vincristine—colon cancer	0.000632	0.00766	CcSEcCtD
Enzalutamide—Epistaxis—Fluorouracil—colon cancer	0.000632	0.00766	CcSEcCtD
Enzalutamide—Rhinitis—Irinotecan—colon cancer	0.000629	0.00763	CcSEcCtD
Enzalutamide—Sinusitis—Fluorouracil—colon cancer	0.000628	0.00761	CcSEcCtD
Enzalutamide—Connective tissue disorder—Irinotecan—colon cancer	0.000617	0.00748	CcSEcCtD
Enzalutamide—ALB—liver—colon cancer	0.000615	0.0174	CbGeAlD
Enzalutamide—Rhinitis—Fluorouracil—colon cancer	0.000603	0.0073	CcSEcCtD
Enzalutamide—Hypoaesthesia—Fluorouracil—colon cancer	0.000598	0.00725	CcSEcCtD
Enzalutamide—Pharyngitis—Fluorouracil—colon cancer	0.000597	0.00723	CcSEcCtD
Enzalutamide—CYP2C19—vagina—colon cancer	0.000587	0.0166	CbGeAlD
Enzalutamide—Angiopathy—Vincristine—colon cancer	0.000585	0.00709	CcSEcCtD
Enzalutamide—Angiopathy—Irinotecan—colon cancer	0.000569	0.0069	CcSEcCtD
Enzalutamide—Mental disorder—Vincristine—colon cancer	0.000565	0.00684	CcSEcCtD
Enzalutamide—Dry skin—Capecitabine—colon cancer	0.000556	0.00675	CcSEcCtD
Enzalutamide—Nasopharyngitis—Capecitabine—colon cancer	0.000543	0.00658	CcSEcCtD
Enzalutamide—Back pain—Vincristine—colon cancer	0.000543	0.00658	CcSEcCtD
Enzalutamide—Sepsis—Methotrexate—colon cancer	0.00054	0.00655	CcSEcCtD
Enzalutamide—Muscular weakness—Capecitabine—colon cancer	0.000535	0.00649	CcSEcCtD
Enzalutamide—AR—liver—colon cancer	0.000534	0.0151	CbGeAlD
Enzalutamide—Back pain—Irinotecan—colon cancer	0.000528	0.00641	CcSEcCtD
Enzalutamide—CYP2B6—lymphoid tissue—colon cancer	0.000527	0.0149	CbGeAlD
Enzalutamide—CYP3A5—digestive system—colon cancer	0.000524	0.0148	CbGeAlD
Enzalutamide—CYP2B6—digestive system—colon cancer	0.00052	0.0147	CbGeAlD
Enzalutamide—CYP2C9—digestive system—colon cancer	0.000515	0.0146	CbGeAlD
Enzalutamide—CYP2C8—vagina—colon cancer	0.000512	0.0145	CbGeAlD
Enzalutamide—Bronchitis—Capecitabine—colon cancer	0.000505	0.00612	CcSEcCtD
Enzalutamide—Vertigo—Vincristine—colon cancer	0.000504	0.00611	CcSEcCtD
Enzalutamide—Leukopenia—Vincristine—colon cancer	0.000502	0.00609	CcSEcCtD
Enzalutamide—CYP2C19—liver—colon cancer	0.000495	0.014	CbGeAlD
Enzalutamide—Vertigo—Irinotecan—colon cancer	0.000491	0.00595	CcSEcCtD
Enzalutamide—Neutropenia—Capecitabine—colon cancer	0.000491	0.00595	CcSEcCtD
Enzalutamide—Leukopenia—Irinotecan—colon cancer	0.000489	0.00593	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Capecitabine—colon cancer	0.000488	0.00591	CcSEcCtD
Enzalutamide—Convulsion—Vincristine—colon cancer	0.000486	0.00589	CcSEcCtD
Enzalutamide—Hypertension—Vincristine—colon cancer	0.000484	0.00587	CcSEcCtD
Enzalutamide—CYP3A4—renal system—colon cancer	0.000479	0.0136	CbGeAlD
Enzalutamide—Hypertension—Irinotecan—colon cancer	0.000472	0.00572	CcSEcCtD
Enzalutamide—ALB—lymph node—colon cancer	0.000471	0.0134	CbGeAlD
Enzalutamide—CYP2D6—renal system—colon cancer	0.000471	0.0133	CbGeAlD
Enzalutamide—Pneumonia—Capecitabine—colon cancer	0.000471	0.0057	CcSEcCtD
Enzalutamide—Leukopenia—Fluorouracil—colon cancer	0.000468	0.00568	CcSEcCtD
Enzalutamide—Infestation NOS—Capecitabine—colon cancer	0.000468	0.00567	CcSEcCtD
Enzalutamide—Infestation—Capecitabine—colon cancer	0.000468	0.00567	CcSEcCtD
Enzalutamide—CYP3A5—vagina—colon cancer	0.000462	0.0131	CbGeAlD
Enzalutamide—CYP2B6—vagina—colon cancer	0.000459	0.013	CbGeAlD
Enzalutamide—Infection—Vincristine—colon cancer	0.000455	0.00551	CcSEcCtD
Enzalutamide—Convulsion—Fluorouracil—colon cancer	0.000453	0.0055	CcSEcCtD
Enzalutamide—Nervous system disorder—Vincristine—colon cancer	0.000449	0.00544	CcSEcCtD
Enzalutamide—Thrombocytopenia—Vincristine—colon cancer	0.000448	0.00543	CcSEcCtD
Enzalutamide—ABCB1—embryo—colon cancer	0.000448	0.0127	CbGeAlD
Enzalutamide—Haematuria—Capecitabine—colon cancer	0.000446	0.00541	CcSEcCtD
Enzalutamide—Infection—Irinotecan—colon cancer	0.000443	0.00537	CcSEcCtD
Enzalutamide—Epistaxis—Capecitabine—colon cancer	0.000441	0.00535	CcSEcCtD
Enzalutamide—Nervous system disorder—Irinotecan—colon cancer	0.000437	0.0053	CcSEcCtD
Enzalutamide—Thrombocytopenia—Irinotecan—colon cancer	0.000437	0.00529	CcSEcCtD
Enzalutamide—CYP2C8—liver—colon cancer	0.000432	0.0122	CbGeAlD
Enzalutamide—Infection—Fluorouracil—colon cancer	0.000424	0.00514	CcSEcCtD
Enzalutamide—Rhinitis—Capecitabine—colon cancer	0.000421	0.0051	CcSEcCtD
Enzalutamide—Nervous system disorder—Fluorouracil—colon cancer	0.000419	0.00508	CcSEcCtD
Enzalutamide—Thrombocytopenia—Fluorouracil—colon cancer	0.000418	0.00507	CcSEcCtD
Enzalutamide—Hypoaesthesia—Capecitabine—colon cancer	0.000418	0.00507	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Vincristine—colon cancer	0.000417	0.00506	CcSEcCtD
Enzalutamide—Pharyngitis—Capecitabine—colon cancer	0.000417	0.00505	CcSEcCtD
Enzalutamide—Urinary tract disorder—Capecitabine—colon cancer	0.000415	0.00503	CcSEcCtD
Enzalutamide—Insomnia—Vincristine—colon cancer	0.000414	0.00502	CcSEcCtD
Enzalutamide—Oedema peripheral—Capecitabine—colon cancer	0.000414	0.00502	CcSEcCtD
Enzalutamide—Connective tissue disorder—Capecitabine—colon cancer	0.000413	0.005	CcSEcCtD
Enzalutamide—Urethral disorder—Capecitabine—colon cancer	0.000412	0.00499	CcSEcCtD
Enzalutamide—Paraesthesia—Vincristine—colon cancer	0.000411	0.00498	CcSEcCtD
Enzalutamide—AR—lymph node—colon cancer	0.00041	0.0116	CbGeAlD
Enzalutamide—Insomnia—Irinotecan—colon cancer	0.000403	0.00489	CcSEcCtD
Enzalutamide—Paraesthesia—Irinotecan—colon cancer	0.0004	0.00485	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Vincristine—colon cancer	0.000395	0.00479	CcSEcCtD
Enzalutamide—Fatigue—Vincristine—colon cancer	0.000395	0.00478	CcSEcCtD
Enzalutamide—CYP3A4—digestive system—colon cancer	0.000393	0.0111	CbGeAlD
Enzalutamide—CYP3A5—liver—colon cancer	0.00039	0.011	CbGeAlD
Enzalutamide—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000389	0.00472	CcSEcCtD
Enzalutamide—CYP2B6—liver—colon cancer	0.000388	0.011	CbGeAlD
Enzalutamide—CYP2D6—digestive system—colon cancer	0.000387	0.0109	CbGeAlD
Enzalutamide—Insomnia—Fluorouracil—colon cancer	0.000386	0.00468	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Irinotecan—colon cancer	0.000385	0.00467	CcSEcCtD
Enzalutamide—Fatigue—Irinotecan—colon cancer	0.000384	0.00466	CcSEcCtD
Enzalutamide—CYP2C9—liver—colon cancer	0.000384	0.0109	CbGeAlD
Enzalutamide—Paraesthesia—Fluorouracil—colon cancer	0.000383	0.00465	CcSEcCtD
Enzalutamide—Angiopathy—Capecitabine—colon cancer	0.000381	0.00462	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000369	0.00447	CcSEcCtD
Enzalutamide—Mental disorder—Capecitabine—colon cancer	0.000368	0.00446	CcSEcCtD
Enzalutamide—ABCB1—epithelium—colon cancer	0.000366	0.0104	CbGeAlD
Enzalutamide—Neutropenia—Methotrexate—colon cancer	0.000365	0.00443	CcSEcCtD
Enzalutamide—Upper respiratory tract infection—Methotrexate—colon cancer	0.000363	0.0044	CcSEcCtD
Enzalutamide—Back pain—Capecitabine—colon cancer	0.000354	0.00429	CcSEcCtD
Enzalutamide—Pneumonia—Methotrexate—colon cancer	0.00035	0.00425	CcSEcCtD
Enzalutamide—Infestation NOS—Methotrexate—colon cancer	0.000348	0.00422	CcSEcCtD
Enzalutamide—Infestation—Methotrexate—colon cancer	0.000348	0.00422	CcSEcCtD
Enzalutamide—ABCB1—renal system—colon cancer	0.000339	0.0096	CbGeAlD
Enzalutamide—Haematuria—Methotrexate—colon cancer	0.000332	0.00403	CcSEcCtD
Enzalutamide—Epistaxis—Methotrexate—colon cancer	0.000329	0.00398	CcSEcCtD
Enzalutamide—Vertigo—Capecitabine—colon cancer	0.000328	0.00398	CcSEcCtD
Enzalutamide—Asthenia—Vincristine—colon cancer	0.000328	0.00398	CcSEcCtD
Enzalutamide—Leukopenia—Capecitabine—colon cancer	0.000327	0.00397	CcSEcCtD
Enzalutamide—Asthenia—Irinotecan—colon cancer	0.00032	0.00388	CcSEcCtD
Enzalutamide—Hypertension—Capecitabine—colon cancer	0.000316	0.00383	CcSEcCtD
Enzalutamide—Diarrhoea—Vincristine—colon cancer	0.000313	0.0038	CcSEcCtD
Enzalutamide—Arthralgia—Capecitabine—colon cancer	0.000311	0.00377	CcSEcCtD
Enzalutamide—Pharyngitis—Methotrexate—colon cancer	0.00031	0.00376	CcSEcCtD
Enzalutamide—Anxiety—Capecitabine—colon cancer	0.00031	0.00376	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000309	0.00375	CcSEcCtD
Enzalutamide—Urinary tract disorder—Methotrexate—colon cancer	0.000309	0.00374	CcSEcCtD
Enzalutamide—Urethral disorder—Methotrexate—colon cancer	0.000306	0.00372	CcSEcCtD
Enzalutamide—Diarrhoea—Irinotecan—colon cancer	0.000305	0.0037	CcSEcCtD
Enzalutamide—Dizziness—Vincristine—colon cancer	0.000303	0.00367	CcSEcCtD
Enzalutamide—Pruritus—Fluorouracil—colon cancer	0.000302	0.00366	CcSEcCtD
Enzalutamide—Infection—Capecitabine—colon cancer	0.000296	0.00359	CcSEcCtD
Enzalutamide—Dizziness—Irinotecan—colon cancer	0.000295	0.00357	CcSEcCtD
Enzalutamide—CYP3A4—liver—colon cancer	0.000293	0.00829	CbGeAlD
Enzalutamide—Nervous system disorder—Capecitabine—colon cancer	0.000293	0.00355	CcSEcCtD
Enzalutamide—Diarrhoea—Fluorouracil—colon cancer	0.000292	0.00354	CcSEcCtD
Enzalutamide—Thrombocytopenia—Capecitabine—colon cancer	0.000292	0.00354	CcSEcCtD
Enzalutamide—Skin disorder—Capecitabine—colon cancer	0.00029	0.00351	CcSEcCtD
Enzalutamide—CYP2D6—liver—colon cancer	0.000288	0.00816	CbGeAlD
Enzalutamide—Headache—Vincristine—colon cancer	0.000287	0.00348	CcSEcCtD
Enzalutamide—Angiopathy—Methotrexate—colon cancer	0.000284	0.00344	CcSEcCtD
Enzalutamide—Dizziness—Fluorouracil—colon cancer	0.000282	0.00342	CcSEcCtD
Enzalutamide—ABCB1—lymphoid tissue—colon cancer	0.000282	0.00797	CbGeAlD
Enzalutamide—Headache—Irinotecan—colon cancer	0.000279	0.00339	CcSEcCtD
Enzalutamide—ABCB1—digestive system—colon cancer	0.000278	0.00788	CbGeAlD
Enzalutamide—Mental disorder—Methotrexate—colon cancer	0.000274	0.00332	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000272	0.0033	CcSEcCtD
Enzalutamide—Insomnia—Capecitabine—colon cancer	0.00027	0.00327	CcSEcCtD
Enzalutamide—Paraesthesia—Capecitabine—colon cancer	0.000268	0.00325	CcSEcCtD
Enzalutamide—Headache—Fluorouracil—colon cancer	0.000268	0.00324	CcSEcCtD
Enzalutamide—Back pain—Methotrexate—colon cancer	0.000263	0.00319	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Capecitabine—colon cancer	0.000258	0.00312	CcSEcCtD
Enzalutamide—Fatigue—Capecitabine—colon cancer	0.000257	0.00312	CcSEcCtD
Enzalutamide—ABCB1—bone marrow—colon cancer	0.000256	0.00726	CbGeAlD
Enzalutamide—ABCB1—vagina—colon cancer	0.000246	0.00695	CbGeAlD
Enzalutamide—Vertigo—Methotrexate—colon cancer	0.000245	0.00296	CcSEcCtD
Enzalutamide—Leukopenia—Methotrexate—colon cancer	0.000244	0.00295	CcSEcCtD
Enzalutamide—Convulsion—Methotrexate—colon cancer	0.000236	0.00286	CcSEcCtD
Enzalutamide—Arthralgia—Methotrexate—colon cancer	0.000232	0.00281	CcSEcCtD
Enzalutamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00023	0.00279	CcSEcCtD
Enzalutamide—Infection—Methotrexate—colon cancer	0.000221	0.00268	CcSEcCtD
Enzalutamide—Nervous system disorder—Methotrexate—colon cancer	0.000218	0.00264	CcSEcCtD
Enzalutamide—Thrombocytopenia—Methotrexate—colon cancer	0.000217	0.00264	CcSEcCtD
Enzalutamide—Skin disorder—Methotrexate—colon cancer	0.000216	0.00262	CcSEcCtD
Enzalutamide—Asthenia—Capecitabine—colon cancer	0.000214	0.0026	CcSEcCtD
Enzalutamide—Pruritus—Capecitabine—colon cancer	0.000211	0.00256	CcSEcCtD
Enzalutamide—ABCB1—liver—colon cancer	0.000207	0.00587	CbGeAlD
Enzalutamide—Diarrhoea—Capecitabine—colon cancer	0.000204	0.00247	CcSEcCtD
Enzalutamide—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000202	0.00245	CcSEcCtD
Enzalutamide—Insomnia—Methotrexate—colon cancer	0.000201	0.00244	CcSEcCtD
Enzalutamide—Paraesthesia—Methotrexate—colon cancer	0.000199	0.00242	CcSEcCtD
Enzalutamide—Dizziness—Capecitabine—colon cancer	0.000197	0.00239	CcSEcCtD
Enzalutamide—Gastrointestinal disorder—Methotrexate—colon cancer	0.000192	0.00232	CcSEcCtD
Enzalutamide—Fatigue—Methotrexate—colon cancer	0.000192	0.00232	CcSEcCtD
Enzalutamide—Headache—Capecitabine—colon cancer	0.000187	0.00227	CcSEcCtD
Enzalutamide—Asthenia—Methotrexate—colon cancer	0.000159	0.00193	CcSEcCtD
Enzalutamide—ABCB1—lymph node—colon cancer	0.000159	0.0045	CbGeAlD
Enzalutamide—Pruritus—Methotrexate—colon cancer	0.000157	0.00191	CcSEcCtD
Enzalutamide—CYP2C8—Metapathway biotransformation—CHST5—colon cancer	0.000153	0.00816	CbGpPWpGaD
Enzalutamide—AR—Nongenotropic Androgen signaling—SRC—colon cancer	0.000153	0.00814	CbGpPWpGaD
Enzalutamide—Diarrhoea—Methotrexate—colon cancer	0.000152	0.00184	CcSEcCtD
Enzalutamide—Dizziness—Methotrexate—colon cancer	0.000147	0.00178	CcSEcCtD
Enzalutamide—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000141	0.00749	CbGpPWpGaD
Enzalutamide—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—colon cancer	0.00014	0.00747	CbGpPWpGaD
Enzalutamide—Headache—Methotrexate—colon cancer	0.000139	0.00169	CcSEcCtD
Enzalutamide—CYP2C19—Metapathway biotransformation—CHST5—colon cancer	0.000137	0.00728	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	0.000129	0.00688	CbGpPWpGaD
Enzalutamide—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	0.000128	0.00683	CbGpPWpGaD
Enzalutamide—CYP2D6—Metapathway biotransformation—CHST5—colon cancer	0.000126	0.0067	CbGpPWpGaD
Enzalutamide—CYP2C9—Metapathway biotransformation—CHST5—colon cancer	0.000125	0.00664	CbGpPWpGaD
Enzalutamide—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	0.000123	0.00657	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—HNF4A—colon cancer	0.000123	0.00656	CbGpPWpGaD
Enzalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	0.000122	0.00651	CbGpPWpGaD
Enzalutamide—AR—FOXA1 transcription factor network—EP300—colon cancer	0.000119	0.00633	CbGpPWpGaD
Enzalutamide—CYP3A4—Irinotecan Pathway—APC—colon cancer	0.000118	0.00629	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—APC—colon cancer	0.000117	0.00621	CbGpPWpGaD
Enzalutamide—AR—Nongenotropic Androgen signaling—PIK3CA—colon cancer	0.000116	0.00619	CbGpPWpGaD
Enzalutamide—AR—Notch-mediated HES/HEY network—EP300—colon cancer	0.000113	0.006	CbGpPWpGaD
Enzalutamide—AR—Nongenotropic Androgen signaling—HRAS—colon cancer	0.000108	0.00573	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—colon cancer	0.000107	0.00572	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	0.000103	0.0055	CbGpPWpGaD
Enzalutamide—AR—Regulation of Androgen receptor activity—EP300—colon cancer	0.000102	0.00545	CbGpPWpGaD
Enzalutamide—AR—Regulation of Androgen receptor activity—SRC—colon cancer	9.95e-05	0.0053	CbGpPWpGaD
Enzalutamide—AR—Coregulation of Androgen receptor activity—CCND1—colon cancer	9.93e-05	0.00529	CbGpPWpGaD
Enzalutamide—AR—Coregulation of Androgen receptor activity—CTNNB1—colon cancer	9.84e-05	0.00524	CbGpPWpGaD
Enzalutamide—AR—Nongenotropic Androgen signaling—AKT1—colon cancer	9.5e-05	0.00506	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—BAX—colon cancer	9.2e-05	0.0049	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—colon cancer	9.17e-05	0.00488	CbGpPWpGaD
Enzalutamide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	9.09e-05	0.00484	CbGpPWpGaD
Enzalutamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	8.49e-05	0.00453	CbGpPWpGaD
Enzalutamide—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—colon cancer	8.45e-05	0.0045	CbGpPWpGaD
Enzalutamide—CYP3A4—Metapathway biotransformation—CHST5—colon cancer	8.22e-05	0.00438	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—ABCB1—colon cancer	8.06e-05	0.0043	CbGpPWpGaD
Enzalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—colon cancer	8.05e-05	0.00429	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—colon cancer	8e-05	0.00426	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—colon cancer	7.92e-05	0.00422	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	7.92e-05	0.00422	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—colon cancer	7.66e-05	0.00408	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	7.63e-05	0.00406	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—colon cancer	7.36e-05	0.00392	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—CCND1—colon cancer	7.34e-05	0.00391	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—EP300—colon cancer	7.29e-05	0.00388	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—CTNNB1—colon cancer	7.27e-05	0.00387	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—CDKN1A—colon cancer	7.1e-05	0.00378	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—EP300—colon cancer	6.76e-05	0.0036	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—BRAF—colon cancer	6.59e-05	0.00351	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—SRC—colon cancer	6.57e-05	0.0035	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—CDH1—colon cancer	6.45e-05	0.00344	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—HNF4A—colon cancer	6.42e-05	0.00342	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—colon cancer	6.41e-05	0.00342	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—MYC—colon cancer	6.35e-05	0.00338	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—DCC—colon cancer	6.25e-05	0.00333	CbGpPWpGaD
Enzalutamide—CYP2C8—Arachidonic acid metabolism—PTGS2—colon cancer	6.03e-05	0.00321	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—APC—colon cancer	5.81e-05	0.0031	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—EGFR—colon cancer	5.76e-05	0.00307	CbGpPWpGaD
Enzalutamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—colon cancer	5.6e-05	0.00298	CbGpPWpGaD
Enzalutamide—AR—Coregulation of Androgen receptor activity—AKT1—colon cancer	5.53e-05	0.00294	CbGpPWpGaD
Enzalutamide—CYP2C19—Arachidonic acid metabolism—PTGS2—colon cancer	5.38e-05	0.00287	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—HNF4A—colon cancer	5.26e-05	0.00281	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CA7—colon cancer	5.17e-05	0.00276	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CA7—colon cancer	5.06e-05	0.00269	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—CASP3—colon cancer	4.94e-05	0.00263	CbGpPWpGaD
Enzalutamide—CYP2C9—Arachidonic acid metabolism—PTGS2—colon cancer	4.91e-05	0.00262	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—CASP3—colon cancer	4.82e-05	0.00257	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—CCND1—colon cancer	4.81e-05	0.00256	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—colon cancer	4.76e-05	0.00254	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—CTNNB1—colon cancer	4.64e-05	0.00247	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—EP300—colon cancer	4.43e-05	0.00236	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	4.41e-05	0.00235	CbGpPWpGaD
Enzalutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—colon cancer	4.4e-05	0.00235	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CA7—colon cancer	4.38e-05	0.00233	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CA7—colon cancer	4.36e-05	0.00232	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—EP300—colon cancer	4.31e-05	0.0023	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—colon cancer	4.21e-05	0.00224	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—VEGFA—colon cancer	4.19e-05	0.00223	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	4.1e-05	0.00218	CbGpPWpGaD
Enzalutamide—AR—SIDS Susceptibility Pathways—VEGFA—colon cancer	4.09e-05	0.00218	CbGpPWpGaD
Enzalutamide—AR—Androgen receptor signaling pathway—AKT1—colon cancer	4.08e-05	0.00218	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	3.99e-05	0.00212	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	3.95e-05	0.0021	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CA7—colon cancer	3.91e-05	0.00208	CbGpPWpGaD
Enzalutamide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—colon cancer	3.87e-05	0.00206	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—MYC—colon cancer	3.86e-05	0.00206	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	3.86e-05	0.00205	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CA7—colon cancer	3.82e-05	0.00203	CbGpPWpGaD
Enzalutamide—ALB—Selenium Micronutrient Network—PTGS2—colon cancer	3.82e-05	0.00203	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—EGFR—colon cancer	3.77e-05	0.00201	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	3.67e-05	0.00196	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CA7—colon cancer	3.6e-05	0.00192	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	3.57e-05	0.0019	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—KRAS—colon cancer	3.57e-05	0.0019	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CA7—colon cancer	3.57e-05	0.0019	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—EP300—colon cancer	3.5e-05	0.00186	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	3.48e-05	0.00185	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—CASP3—colon cancer	3.38e-05	0.0018	CbGpPWpGaD
Enzalutamide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—colon cancer	3.34e-05	0.00178	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—colon cancer	3.31e-05	0.00177	CbGpPWpGaD
Enzalutamide—ALB—Platelet degranulation—VEGFA—colon cancer	3.24e-05	0.00173	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—colon cancer	3.23e-05	0.00172	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	3.2e-05	0.0017	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	3.19e-05	0.0017	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—TP53—colon cancer	3.17e-05	0.00169	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—CHST5—colon cancer	3.14e-05	0.00167	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—ODC1—colon cancer	3.14e-05	0.00167	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	3.13e-05	0.00167	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—colon cancer	3.11e-05	0.00166	CbGpPWpGaD
Enzalutamide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—colon cancer	3.09e-05	0.00165	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—HNF4A—colon cancer	3.09e-05	0.00165	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—ODC1—colon cancer	3.06e-05	0.00163	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—CHST5—colon cancer	3.06e-05	0.00163	CbGpPWpGaD
Enzalutamide—ALB—Platelet degranulation—TGFB1—colon cancer	2.98e-05	0.00159	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	2.95e-05	0.00157	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—VEGFA—colon cancer	2.87e-05	0.00153	CbGpPWpGaD
Enzalutamide—ALB—Folate Metabolism—TP53—colon cancer	2.86e-05	0.00152	CbGpPWpGaD
Enzalutamide—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—colon cancer	2.84e-05	0.00151	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—PPARG—colon cancer	2.79e-05	0.00148	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	2.71e-05	0.00145	CbGpPWpGaD
Enzalutamide—AR—Integrated Breast Cancer Pathway—AKT1—colon cancer	2.68e-05	0.00143	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—ODC1—colon cancer	2.65e-05	0.00141	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—CHST5—colon cancer	2.65e-05	0.00141	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—ODC1—colon cancer	2.64e-05	0.00141	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—CHST5—colon cancer	2.64e-05	0.00141	CbGpPWpGaD
Enzalutamide—ABCB1—Allograft Rejection—TGFB1—colon cancer	2.63e-05	0.0014	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	2.63e-05	0.0014	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—ODC1—colon cancer	2.37e-05	0.00126	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—CHST5—colon cancer	2.37e-05	0.00126	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—APC—colon cancer	2.37e-05	0.00126	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CA7—colon cancer	2.35e-05	0.00125	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—CHST5—colon cancer	2.31e-05	0.00123	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—ODC1—colon cancer	2.31e-05	0.00123	CbGpPWpGaD
Enzalutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	2.22e-05	0.00118	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ODC1—colon cancer	2.18e-05	0.00116	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—CHST5—colon cancer	2.18e-05	0.00116	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ODC1—colon cancer	2.16e-05	0.00115	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—CHST5—colon cancer	2.16e-05	0.00115	CbGpPWpGaD
Enzalutamide—ABCB1—HIF-1-alpha transcription factor network—AKT1—colon cancer	2.11e-05	0.00113	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—colon cancer	1.8e-05	0.000958	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—colon cancer	1.67e-05	0.000889	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—colon cancer	1.62e-05	0.000866	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—colon cancer	1.61e-05	0.000857	CbGpPWpGaD
Enzalutamide—AR—Generic Transcription Pathway—MYC—colon cancer	1.59e-05	0.000846	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—colon cancer	1.57e-05	0.000837	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—colon cancer	1.5e-05	0.000797	CbGpPWpGaD
Enzalutamide—ALB—Transmembrane transport of small molecules—ABCB1—colon cancer	1.49e-05	0.000793	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—SRC—colon cancer	1.48e-05	0.000787	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—colon cancer	1.45e-05	0.000775	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—VEGFA—colon cancer	1.44e-05	0.000766	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—CHST5—colon cancer	1.42e-05	0.000759	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ODC1—colon cancer	1.42e-05	0.000759	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—colon cancer	1.42e-05	0.000755	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—PPARG—colon cancer	1.34e-05	0.000715	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—TGFB1—colon cancer	1.32e-05	0.000703	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—colon cancer	1.3e-05	0.000694	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—colon cancer	1.3e-05	0.000693	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—colon cancer	1.27e-05	0.000679	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—colon cancer	1.2e-05	0.000642	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—PIK3CA—colon cancer	1.12e-05	0.000599	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—colon cancer	1.11e-05	0.000589	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.1e-05	0.000584	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PPARG—colon cancer	1.09e-05	0.00058	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—colon cancer	1.07e-05	0.00057	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—colon cancer	9.78e-06	0.000521	CbGpPWpGaD
Enzalutamide—ALB—Platelet activation, signaling and aggregation—AKT1—colon cancer	9.18e-06	0.000489	CbGpPWpGaD
Enzalutamide—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—colon cancer	9.04e-06	0.000482	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—colon cancer	8.92e-06	0.000475	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.62e-06	0.000459	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	8.57e-06	0.000457	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—ABCB1—colon cancer	8.28e-06	0.000441	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—TYMS—colon cancer	8.14e-06	0.000433	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—ABCB1—colon cancer	8.1e-06	0.000431	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—TYMS—colon cancer	7.95e-06	0.000424	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—EP300—colon cancer	7.83e-06	0.000417	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	7.69e-06	0.00041	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—MYC—colon cancer	7.65e-06	0.000407	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—SRC—colon cancer	7.61e-06	0.000406	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—VEGFA—colon cancer	7.42e-06	0.000395	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—NRAS—colon cancer	7.32e-06	0.00039	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.17e-06	0.000382	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—EP300—colon cancer	7.13e-06	0.00038	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—colon cancer	7.01e-06	0.000374	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—ABCB1—colon cancer	7.01e-06	0.000374	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—ABCB1—colon cancer	6.97e-06	0.000372	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—TYMS—colon cancer	6.89e-06	0.000367	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—TYMS—colon cancer	6.85e-06	0.000365	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—TGFB1—colon cancer	6.81e-06	0.000363	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—colon cancer	6.4e-06	0.000341	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—KRAS—colon cancer	6.3e-06	0.000336	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—ABCB1—colon cancer	6.26e-06	0.000334	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—TYMS—colon cancer	6.15e-06	0.000328	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—TYMS—colon cancer	6e-06	0.00032	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—colon cancer	5.83e-06	0.000311	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—PIK3CA—colon cancer	5.79e-06	0.000309	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PPARG—colon cancer	5.76e-06	0.000307	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—ABCB1—colon cancer	5.76e-06	0.000307	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—ABCB1—colon cancer	5.71e-06	0.000304	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—TYMS—colon cancer	5.66e-06	0.000301	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PPARG—colon cancer	5.63e-06	0.0003	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—TYMS—colon cancer	5.61e-06	0.000299	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—TP53—colon cancer	5.6e-06	0.000299	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—HRAS—colon cancer	5.36e-06	0.000285	CbGpPWpGaD
Enzalutamide—AR—Gene Expression—AKT1—colon cancer	5.3e-06	0.000283	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.3e-06	0.000283	CbGpPWpGaD
Enzalutamide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	5.27e-06	0.000281	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PPARG—colon cancer	4.88e-06	0.00026	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PPARG—colon cancer	4.85e-06	0.000259	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.73e-06	0.000252	CbGpPWpGaD
Enzalutamide—ALB—Hemostasis—AKT1—colon cancer	4.73e-06	0.000252	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PTGS2—colon cancer	4.53e-06	0.000242	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PTGS2—colon cancer	4.43e-06	0.000236	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PPARG—colon cancer	4.36e-06	0.000232	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—colon cancer	4.32e-06	0.00023	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PPARG—colon cancer	4.25e-06	0.000226	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PPARG—colon cancer	4.01e-06	0.000213	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PPARG—colon cancer	3.97e-06	0.000212	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PTGS2—colon cancer	3.84e-06	0.000205	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PTGS2—colon cancer	3.82e-06	0.000203	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—EP300—colon cancer	3.77e-06	0.000201	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—ABCB1—colon cancer	3.76e-06	0.000201	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—TYMS—colon cancer	3.7e-06	0.000197	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—EP300—colon cancer	3.69e-06	0.000196	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PTGS2—colon cancer	3.43e-06	0.000183	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PTGS2—colon cancer	3.34e-06	0.000178	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—EP300—colon cancer	3.19e-06	0.00017	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—EP300—colon cancer	3.17e-06	0.000169	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PTGS2—colon cancer	3.15e-06	0.000168	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PTGS2—colon cancer	3.12e-06	0.000166	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—EP300—colon cancer	2.85e-06	0.000152	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—PIK3CA—colon cancer	2.79e-06	0.000149	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—EP300—colon cancer	2.78e-06	0.000148	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—PIK3CA—colon cancer	2.73e-06	0.000145	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—EP300—colon cancer	2.62e-06	0.00014	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PPARG—colon cancer	2.62e-06	0.00014	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—EP300—colon cancer	2.6e-06	0.000138	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—PIK3CA—colon cancer	2.36e-06	0.000126	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—PIK3CA—colon cancer	2.35e-06	0.000125	CbGpPWpGaD
Enzalutamide—CYP2B6—Metabolism—AKT1—colon cancer	2.28e-06	0.000121	CbGpPWpGaD
Enzalutamide—CYP3A5—Metabolism—AKT1—colon cancer	2.23e-06	0.000119	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—PIK3CA—colon cancer	2.11e-06	0.000112	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PTGS2—colon cancer	2.06e-06	0.00011	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—PIK3CA—colon cancer	2.06e-06	0.00011	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—PIK3CA—colon cancer	1.94e-06	0.000103	CbGpPWpGaD
Enzalutamide—CYP2C8—Metabolism—AKT1—colon cancer	1.93e-06	0.000103	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—PIK3CA—colon cancer	1.92e-06	0.000102	CbGpPWpGaD
Enzalutamide—ALB—Metabolism—AKT1—colon cancer	1.92e-06	0.000102	CbGpPWpGaD
Enzalutamide—CYP2C19—Metabolism—AKT1—colon cancer	1.72e-06	9.17e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—EP300—colon cancer	1.71e-06	9.13e-05	CbGpPWpGaD
Enzalutamide—ABCB1—Metabolism—AKT1—colon cancer	1.68e-06	8.95e-05	CbGpPWpGaD
Enzalutamide—CYP2D6—Metabolism—AKT1—colon cancer	1.58e-06	8.44e-05	CbGpPWpGaD
Enzalutamide—CYP2C9—Metabolism—AKT1—colon cancer	1.57e-06	8.37e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—PIK3CA—colon cancer	1.27e-06	6.75e-05	CbGpPWpGaD
Enzalutamide—CYP3A4—Metabolism—AKT1—colon cancer	1.04e-06	5.52e-05	CbGpPWpGaD
